| CEO Name | Emma Walmsley |
| Nationality | United Kingdom |
| Net Worth Estimation | $40 million |
Emma Walmsley, CEO of GlaxoSmithKline plc (GSK), has an estimated net worth of around $40 million due to her multi-million dollar annual salary, performance-based bonuses, and substantial shareholdings in GSK. Her compensation is also boosted by long-term incentive plans and dividends from her stock portfolio, reflecting her leadership role in a global pharmaceutical company.
Emma Walmsley's estimated net worth of $40,000,000 places her at the midpoint (44%) between the minimum ($10,000,000) and maximum ($90,000,000) CEO net worths in the healthcare business category. This positions her well within the typical range for CEOs in her industry.
Business Category: Healthcare
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 90000000 USD
Emma Walmsley Performance in GlaxoSmithKline plc (GSK)
Emma Walmsley, CEO of GlaxoSmithKline plc (GSK), demonstrates strategic leadership and data-driven decision-making focused on innovation in pharmaceuticals and consumer healthcare. Her performance has driven GSK's transformation through streamlined operations, increased R&D investments, and strategic portfolio reshaping, notably advancing vaccines and specialty medicines. Walmsley's impact includes enhanced shareholder value, strengthened global market position, and accelerated drug development pipelines, solidifying GSK's competitiveness in the healthcare sector.
Latest News
GSK CEO Emma Walmsley Steps Down, Luke Miels Named Successor
Emma Walmsley, GSK's CEO since 2017 and the first woman to lead a big pharma company, will step down on December 31, 2025. Luke Miels, an insider with experience at AstraZeneca and Roche, is appointed as the next CEO; Walmsley will support the transition until September 2026. Meanwhile, GSK reports strong Q3 2025 performance and plans significant R&D investments in the U.S..
Source: http://www.gsk.com/en-gb/media/press-releases/ and http://www.biopharmadive.com/news/emma-walmsley-retire-gsk-ceo-luke-miels/761344/